高齢化社会を迎え、パーキンソン病、アルツハイマー症などの中枢神経系に障害を生じる神経変性疾患の患者数はますます増大する傾向にあり、これらの神経変性疾患に対する治療薬研究・開発が激化しています。株式会社安評センターでは日本における神経変性疾患の研究・開発をサポートするために、世界的に評価の高いオーストリアのQPS社（QPS Austria GmbH）のサービスを日本代理店として提供いたします。
QPS社の神経薬理学部門は、神経変性疾患に特化したCRO、JSW Life Sciences社としてオーストリアのグラーツに1999年に設立され、その後QPS社に統合されました。パーキンソン病、アルツハイマー症など神経変性疾患の分野において、その科学レベル、技術レベルは高く評価され、世界の大手製薬企業から多くの試験の受託実績があります。QPS社では様々な神経変性疾患の創薬において、in vitro、in vivoの非臨床試験から、臨床試験までの受託・コンサルタントサービスを行っております。特に非臨床薬理試験においては、病態モデルとなる遺伝子改変動物を用いたユニークな薬物評価系を保有しています。
QPS Austria
GmbH概要
QPS社の神経薬理学部門は、神経変性疾患に特化したCRO、JSW Life Sciences社としてオーストリアのグラーツに1999年に設立され、その後QPS社に統合されました。パーキンソン病、アルツハイマー症など神経変性疾患の分野において、その科学レベル、技術レベルは高く評価され、世界の大手製薬企業から多くの試験の受託実績があります。当社はQPS社の非臨床試験に関する日本代理店となっております。
in vivo 評価系
| Indication | Strain Name | Species | Mutation | |
|---|---|---|---|---|
| Construct | Promoter | |||
| Alzheimer Disease human APP/Aβ |
APPSL | Mouse | human APP751SL-h London (717) & Swedish (670/671) mutation | murine Thy-1 |
| Tg2576 | human APP695 with double mutations at KM670/671NL | hamster prion protein gene | ||
| 5xFAD | human APPSwFlLon, PSEN1 * M146L * L286V 6799Vas/J | murine Thy-1 | ||
| Alzheimer Disease human TAU |
TMHT10 hTau (V337M, R406W) | Mouse | human TAU441 bearing the missense mutations V337M and R406W | murine Thy-1 |
| PS19 | T34 isoform; 4 microtubule binding repeats (IN4R) of tau with P301S mutation | murine prion | ||
| genomic Tau | 6 human Tau isoforms, no endogenous Tau | human Tau | ||
| Alzheimer Disease crossbreds |
APPSL x hQC | Mouse | human APP751SL-h London (717) & Swedish (670/671) mutations & hQC | murine Thy-1 |
| 5xFAD x hQC | human APPSwFlLon, PSEN1 * M146L * L286V 6799Vas/J & hQC | |||
| Parkinson’s Disease | D-Line | Mouse | wildtype human α-synuclein | PDGF-β |
| Line-61 | murine Thy-1 | |||
| A53T-Sud | human α-synuclein with mutation A53T | |||
| Huntington’s Disease | R6/2 | Mouse | human Huntington with 110-125 CAG repeat expansions | ー |
| zQ175 | Murine exon 1 of Htt replaced by human Htt exon 1 (180-220 CAG repeats) | murine Htt | ||
| BAC HD | Rat | human Huntington with CAG repeat expansions | rat HD | |
| ALS | (SOD1-G93A)1Gur/J | Mouse | human SOD1 with G93A mutation-high copy number | murine Thy-1 |
| human SOD1 with G93A mutation-low copy number | ||||
| ALS-FTLD | TDP43 | Mouse | human wildtype Tar DNA Binding Protein-43 | murine Thy-1 |
| Niemann-Pick disease type C1 | NPC1-/- | Mouse | knockout | ー |
| Gaucher Disease | 4L/PS-NA | Mouse | Homozygous GbaV394L/V394L mutation; prosaposin knockout (PS-/-); homozygous prosaposin transgene (NA) | ー |
| GBA D409V KI | Targeted mutation resulting in murine D427V β-glucosidase (Gba) protein, corresponding to human D409V mutation; loxP sites flank exons 6 to 8 | |||
| Pompe Disease | 6neo | Mouse | Α-glucosidase (Gaa) knockout | ー |
| Autism | BTBR T+tf/J | Mouse | Inbred strain | ー |
| Autoinflammatory diseases (CAPS) | Nlrp3A350VneoR | Mouse | Point mutation in exon 3 of cryopyrin (Nlrp3) gene, resulting in A350V missense mutation, corresponding to human amino acid 352 | ー |
| Alport | Col4a3-/- | Mouse | knockout | ー |
in vitro 評価系
| Indication | Cell system | Model/Lesion/Stimulation | Readout |
|---|---|---|---|
| Parkinson’s Disease | Primary TH neurons | Compound effect on survival and apoptosis determined by image-based analysis using TH, MAP2 and Annexin V (or cleaved caspase 3) |
|
| Compound effect on synapses by image-based analysis using synapsin, MAP2 and TH | Synapses in TH positive and MAP2 positive neurons | ||
| Compound effect on dendritic network by image-based analysis using TH and tubulin | Dendritic network of TH neurons (outgrowth determined as immunoreactive area) | ||
| PD relevant lesions (e.g. MPP+, 6-OHDA) in combination with image -based analysis |
|
||
| Hippocampal neurons | Compound effect on neurogenesis | BrdU incorporation (image-based analysis) | |
| SH-SY5Y overexpressing wild-type α-synuclein and B103 cells overexpressing A53Tα-synuclein |
|
|
|
| Primary cortical and hippocampal neurons | PD relevant lesions (MMP+, 6-OHDA) |
|
|
| Primary human fibroblasts from PD patients | MMP+ / 6-OHDA lesion |
|
|
| Amyotrophic Lateral Sclerosis (ALS) | Motor neurons (NSC-34) | Glutamate lesion |
|
| Primary cortical or hippocampal neurons |
|
||
| SH-SY5Y cells overexpressing TDP43 |
|
|
|
| Huntington’s Disease | Primary cortical or striatal neurons | Glutamate lesion |
|
| Stroke | Primary neurons | Glutamate or NMDA lesion |
|
| Alzheimer’s Disease | SH-SY5Y | Aβ toxicity assay |
|
| Hippocampal neurons | |||
| SH-SY5Y-hTau441 | Compound effect on total tau and ptau levels by immunosorbent assay | Total Tau and phospho Tau (sites 202, 231, 262, 396, 181 by MSD) | |
| Tau seeding and uptake | Tau aggregation (Cisbio) | ||
| Hippocampal neurons | Compound effect on neurite outgrowth by image based analysis using β-tubulin III |
|
|
| Compound effect on neurogenesis | BrdU Incorporation (image-based analysis) | ||
| Cells overexpressing APP Primary neurons | APP processing, γ-secretase inhibitor | APP, Aβ peptides (MSD) | |
| Microglial cell lines (Bv-2, C6, HMO6) | Inflammation | Cytokines, oxidative stress | |
| Microglial cell lines (BV) | Amyloid clearance assay | Amyloid peptides in supernatant and cell lysate (MSD) | |
| SH-SY5Y-hTau441 | Screening for kinase inhibitors | Total tau and phospho tau (sites 202, 231, 262, 396, 181 by MSD) | |
| No cells | Tau aggregation and dis-aggregation assay | Fluorescent based detection Transmission Electron Microscopy | |
| Inhibition of Amyloid oligomer formation | Determination of amyloid oligomers (modified A4 assay) | ||
| Inflammation | Microglial cell lines (BV-2) | Inflammation stimulated by LPS |
|
| Primary mouse microglia |
|
||
| Organotypic brain slices | Cytokine levels (MSD) | ||
| Gaucher Disease | Mouse embryonic fibroblasts | Compound effect |
|
価格
お客様のご要望を伺って試験系および費用のお見積もりを提案いたします。お問い合わせください。